STOCK TITAN
  1. Home
  2. Sec-filings
  3. HELP
  4. [6-K] CYBIN INC. Current Report (Foreign Issuer)

Cybin shareholders back Helus Pharma name change

Eight nominees were elected for the ensuing year, and shareholders set the board at eight directors.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Cybin Inc. (HELP) said shareholders approved changing its legal name to Helus Pharma Inc., effective October 1, 2026. The name-change resolution received 46,134,602 votes in favor, or 99.315% of votes cast. Shareholders also approved setting the board at eight directors, with 46,139,333 votes in favor, or 99.326%.

At the September 22, 2026 meeting, 107 shareholders represented 46,452,598 common shares, equal to 63.58% of issued and outstanding common shares as of the meeting’s record date. Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So were elected as directors for the ensuing year or until successors are elected or appointed. Zeifmans LLP was appointed auditor until the next annual meeting.

Positive

  • None.

Negative

  • None.
Votes for name-change resolution 46,134,602 votes September 22, 2026 shareholder meeting
Name-change votes in favor 99.315% Percentage reported for votes in favor
Votes for board-size resolution 46,139,333 votes Resolution setting the board at eight directors
Board-size resolution votes in favor 99.326% Percentage reported for votes in favor
Common shares represented 46,452,598 common shares Held by 107 shareholders represented at the meeting
Shares represented as a portion of issued and outstanding shares 63.58% As of the meeting’s record date
Approved board size 8 directors Set by shareholder resolution
serotonergic agonists medical
"developing novel serotonergic agonists (“NSAs”)"
Serotonergic agonists are drugs or compounds that activate the brain’s serotonin receptors, acting like keys that turn on specific cellular “locks” involved in mood, sleep, pain, and other bodily functions. Investors watch them because their ability to treat common or hard-to-treat conditions can create large markets, raise regulatory and safety questions, and affect a drug maker’s revenue and valuation depending on clinical trial results, approvals, patents and side-effect profiles.
Breakthrough Therapy Designation regulatory
"received Breakthrough Therapy Designation from the U.S. Food and Drug Administration"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
adjunctive treatment medical
"for the adjunctive treatment of major depressive disorder"
An adjunctive treatment is a therapy given in addition to a primary treatment to improve overall effectiveness or manage side effects—think of it as a booster or supportive sidekick to the main medicine. For investors, adjunctive therapies matter because they can expand a product’s market use, create additional revenue streams, affect regulatory pathways and clinical trial design, and influence competitive positioning and pricing in a therapeutic area.
issued and outstanding common shares financial
"63.58% of Helus’s total issued and outstanding common shares"
The total number of issued and outstanding common shares is the count of a company's common stock that has been created and is currently held by shareholders, excluding any shares the company has bought back and holds in its treasury. It matters to investors because it determines each shareholder's ownership slice, voting power, market capitalization and per-share metrics like earnings per share—think of the company as a pie and these shares as the slices distributed among owners.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many votes supported the Cybin Inc. (HELP) name change?
The name-change resolution received 46,134,602 votes in favor, or 99.315% of votes cast. The resolution changes the company’s name from Cybin Inc. to Helus Pharma Inc., or another name the directors may approve.

How much of Cybin Inc. (HELP)'s share base was represented at the meeting?
107 shareholders represented 46,452,598 common shares, equal to 63.58% of issued and outstanding common shares as of the meeting’s record date.

What board resolutions and director elections did Cybin Inc. (HELP) report?
Shareholders approved setting the board at eight directors, with 46,139,333 votes for, or 99.326%. Theresa Firestone, Grant Froese, Paul Glavine, Michael Halstead, Eric Hoskins, Mark Lawson, Freda Lewis-Hall and Eric So were elected as directors.

Who was appointed auditor of Cybin Inc. (HELP)?
Zeifmans LLP was appointed auditor until the next annual meeting of shareholders. The directors will fix the auditor’s remuneration.

What clinical programs did Cybin Inc. (HELP) describe?
HLP003 was described as being in Phase 3 clinical development for adjunctive treatment of major depressive disorder and as having Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004 was described as being in Phase 2 for generalized anxiety disorder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2026.
Commission File Number: 001-40673


Cybin Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CYBIN INC.
(Registrant)
Date:September 22, 2026By:
/s/ Greg Cavers
Name:Greg Cavers
Title:Chief Financial Officer




EXHIBIT INDEX

99.1
News Release dated September 22, 2026
99.2
Report of Voting Results




image.jpg

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
TORONTO, CANADA – September 22, 2026 – Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.
The Company is also pleased to announce that, effective October 1, 2026, the Company’s legal name will be changed from “Cybin Inc.” to “Helus Pharma Inc.”. The legal name change follows the Company’s adoption of the business name “Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated transformation from a clinical stage discovery and development company to a commercial-ready pharmaceutical company.
1.    Appointment of Auditor
Zeifmans LLP was appointed auditor of Helus until the next annual meeting of shareholders at renumeration to be fixed by the directors of Helus. Voting results are set out below:
Votes For
Votes Withheld
#
%
#
%
46,084,004
99.207
368,593
0.793

2.    Number of Directors
The special resolution to set the number of directors of Helus at eight was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
Votes For
Votes Against
#
%
#
%
46,139,333
99.326
313,263
0.674


3.    Name Change
The special resolution to change the name of the Company from “Cybin Inc.” to “Helus Pharma Inc.” or such other name as may be approved by the directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
Votes For
Votes Against
#
%
#
%
46,134,602
99.315
317,994
0.685

4.    Election of Directors
Each of the nominees for election as director listed in Helus’s management information circular dated August 18, 2026 were elected as directors of Helus for the ensuing year or until their successors are elected or appointed. Voting results are set out below:

Votes For
Votes Withheld

#
%
#
%
Theresa Firestone
31,992,429
99.239
245,371
0.761
Grant Froese
32,147,160
99.719
90,640
0.281
Paul Glavine
23,072,248
71.569
9,165,552
28.431
Michael Halstead
23,089,890
71.624
9,147,910
28.376
Eric Hoskins
30,895,235
95.835
1,342,565
4.165
Mark Lawson
32,156,082
99.747
81,718
0.253
Freda Lewis-Hall
23,063,327
71.541
9,174,473
28.459
Eric So
22,795,634
71.321
9,166,471
28.679

About Helus Pharma
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.



The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.

Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to transform from a clinical stage discovery and development company to a commercial-ready pharmaceutical company; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

Any forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company’s operations; and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended June 30, 2026 and the Company’s annual information form for the year ended March 31, 2026, which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic


compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Company’s performance and operations.

Neither Cboe Canada nor the Nasdaq Global Market stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com

Gabriel Fahel
Chief Legal Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com

Media Contact:
Victoria Verdeja
RXMD
Public Relations Director
(212) 537-9495
vverdeja@rxmedyn.com



image_0.jpg

REPORT OF VOTING RESULTS
SECTION 11.3 OF NATIONAL INSTRUMENT 51-102

In accordance with section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations, the following is a summary of the results of matters voted on at the annual and special meeting of the holders of the common shares (the “Shareholders”) of Cybin Inc. d/b/a Helus Pharma (“Helus”) held on September 22, 2026 (the “Meeting”).
There were 107 Shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus’s total issued and outstanding common shares as at the record date for the Meeting. As the Meeting was held virtually, all resolutions were passed by a ballot vote.
1.    Appointment of Auditor
Zeifmans LLP was appointed auditor of Helus until the next annual meeting of shareholders at renumeration to be fixed by the directors of Helus. Voting results are set out below:
Votes For
Votes Withheld
#
%
#
%
46,084,004
99.207
368,593
0.793

2.    Number of Directors
The special resolution to set the number of directors of Helus at eight was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:
Votes For
Votes Against
#
%
#
%
46,139,333
99.326
313,263
0.674

3.    Name Change
The special resolution to change the name of Helus from “Cybin Inc.” to “Helus Pharma Inc.” or such other name as may be approved by the directors, was approved by at least two-thirds of the votes cast by the shareholders who voted in respect of the resolution present or represented by proxy at the Meeting. Voting results are set out below:



Votes For
Votes Against
#
%
#
%
46,134,602
99.315
317,994
0.685

4.    Election of Directors
Each of the nominees for election as directors listed in Helus’s management information circular dated August 18, 2026 were elected as directors of Helus for the ensuing year or until their successors are elected or appointed. Voting results are set out below:

Votes For
Votes Withheld

#
%
#
%
Theresa Firestone
31,992,429
99.239
245,371
0.761
Grant Froese
32,147,160
99.719
90,640
0.281
Paul Glavine
23,072,248
71.569
9,165,552
28.431
Michael Halstead
23,089,890
71.624
9,147,910
28.376
Eric Hoskins
30,895,235
95.835
1,342,565
4.165
Mark Lawson
32,156,082
99.747
81,718
0.253
Freda Lewis-Hall
23,063,327
71.541
9,174,473
28.459
Eric So
22,795,634
71.321
9,166,471
28.679


- 2 -

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Keep reading

More on HELP

Trending in the feed

Open the live feed